124 related articles for article (PubMed ID: 23009609)
1. A woman with breast cancer and severe impaired lactose tolerance: an intriguing therapeutic dilemma.
Zagouri F; Dimitrakakis C; Dimopoulos MA; Tsigginou A; Antsaklis A; Papadimitriou CA
Breast J; 2012; 18(6):628-9. PubMed ID: 23009609
[No Abstract] [Full Text] [Related]
2. Cost-effectiveness of extended adjuvant letrozole therapy after 5 years of adjuvant tamoxifen therapy in postmenopausal women with early-stage breast cancer.
Delea TE; Karnon J; Smith RE; Johnston SR; Brandman J; Sung JC; Gross PE
Am J Manag Care; 2006 Jul; 12(7):374-86. PubMed ID: 16834524
[TBL] [Abstract][Full Text] [Related]
3. ATAC trial update.
Del Mastro L; Venturini M
Lancet; 2005 Apr 2-8; 365(9466):1225; author reply 1225-6. PubMed ID: 15811447
[No Abstract] [Full Text] [Related]
4. Tamoxifen and anastrozole as a sequencing strategy: a randomized controlled trial in postmenopausal patients with endocrine-responsive early breast cancer from the Austrian Breast and Colorectal Cancer Study Group.
Dubsky PC; Jakesz R; Mlineritsch B; Pöstlberger S; Samonigg H; Kwasny W; Tausch C; Stöger H; Haider K; Fitzal F; Singer CF; Stierer M; Sevelda P; Luschin-Ebengreuth G; Taucher S; Rudas M; Bartsch R; Steger GG; Greil R; Filipcic L; Gnant M
J Clin Oncol; 2012 Mar; 30(7):722-8. PubMed ID: 22271481
[TBL] [Abstract][Full Text] [Related]
5. Impact of tamoxifen on the pharmacokinetics and endocrine effects of the aromatase inhibitor letrozole in postmenopausal women with breast cancer.
Dowsett M; Pfister C; Johnston SR; Miles DW; Houston SJ; Verbeek JA; Gundacker H; Sioufi A; Smith IE
Clin Cancer Res; 1999 Sep; 5(9):2338-43. PubMed ID: 10499602
[TBL] [Abstract][Full Text] [Related]
6. Aromatase inhibitor-induced carpal tunnel syndrome: results from the ATAC trial.
Sestak I; Sapunar F; Cuzick J
J Clin Oncol; 2009 Oct; 27(30):4961-5. PubMed ID: 19752338
[TBL] [Abstract][Full Text] [Related]
7. Third-generation aromatase inhibitors in the treatment of advanced breast cancer.
Nabholtz JM; Reese DM
Breast Cancer; 2001; 8(4):305-9. PubMed ID: 11791122
[No Abstract] [Full Text] [Related]
8. Anastrozole-induced hepatotoxicity.
Zapata E; Zubiaurre L; Bujanda L; Piérola A
Eur J Gastroenterol Hepatol; 2006 Nov; 18(11):1233-4. PubMed ID: 17033446
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of tamoxifen plus letrozole with assessment of pharmacokinetic interaction in postmenopausal women with metastatic breast cancer.
Ingle JN; Suman VJ; Johnson PA; Krook JE; Mailliard JA; Wheeler RH; Loprinzi CL; Perez EA; Jordan VC; Dowsett M
Clin Cancer Res; 1999 Jul; 5(7):1642-9. PubMed ID: 10430063
[TBL] [Abstract][Full Text] [Related]
10. Inappropriate ATAC on tamoxifen.
Coates A; Mouridsen H; Thürlimann B;
Lancet Oncol; 2008 Apr; 9(4):315-6. PubMed ID: 18374287
[No Abstract] [Full Text] [Related]
11. Letrozole or tamoxifen in early breast cancer.
Buzdar AU; Baum M; Cuzick J
N Engl J Med; 2006 Apr; 354(14):1528-30; author reply 1528-30. PubMed ID: 16598051
[No Abstract] [Full Text] [Related]
12. [New strategies against breast carcinoma. To outwit the resistance tendency of tumor cells].
Jakesz R
MMW Fortschr Med; 2005 Mar; 147(10):8. PubMed ID: 15803774
[No Abstract] [Full Text] [Related]
13. Clinically occult cutaneous metastases.
Resnik KS; DiLeonardo M; Gibbons G
J Am Acad Dermatol; 2006 Dec; 55(6):1044-7. PubMed ID: 17110220
[TBL] [Abstract][Full Text] [Related]
14. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses.
Baum M; Buzdar A; Cuzick J; Forbes J; Houghton J; Howell A; Sahmoud T;
Cancer; 2003 Nov; 98(9):1802-10. PubMed ID: 14584060
[TBL] [Abstract][Full Text] [Related]
15. [Campaign against breast cancer. Are aromatase inhibitors the better choice? (interview by Dr. Dorothea Dlugosch)].
Bruntsch U
MMW Fortschr Med; 2002 Sep; 144(38):20. PubMed ID: 12395697
[No Abstract] [Full Text] [Related]
16. Gallbladder metastases of breast cancer: from clinical-pathological patterns to diagnostic and therapeutic strategy.
Di Vita M; Zanghì A; Lanzafame S; Cavallaro A; Piccolo G; Berretta M; Grosso G; Cappellani A
Clin Ter; 2011; 162(5):451-6. PubMed ID: 22041804
[TBL] [Abstract][Full Text] [Related]
17. Influence of concurrent anastrozole on acute and late side effects of whole breast radiotherapy.
Valakh V; Trombetta MG; Werts ED; Labban G; Khalid MK; Kaminsky A; Parda D
Am J Clin Oncol; 2011 Jun; 34(3):245-8. PubMed ID: 20622644
[TBL] [Abstract][Full Text] [Related]
18. The differences in outcome between ATAC and BIG 1-98 suggest efficacy differences between these two nonsteroidal AIs.
Mouridsen HT
Cancer Invest; 2010; 28 Suppl 1():1-3. PubMed ID: 20653402
[No Abstract] [Full Text] [Related]
19. Impact of body mass index on the efficacy of endocrine therapy in premenopausal patients with breast cancer: an analysis of the prospective ABCSG-12 trial.
Pfeiler G; Königsberg R; Fesl C; Mlineritsch B; Stoeger H; Singer CF; Pöstlberger S; Steger GG; Seifert M; Dubsky P; Taucher S; Samonigg H; Bjelic-Radisic V; Greil R; Marth C; Gnant M
J Clin Oncol; 2011 Jul; 29(19):2653-9. PubMed ID: 21555684
[TBL] [Abstract][Full Text] [Related]
20. Anastrozole for breast cancer: recent advances and ongoing challenges.
Buzdar AU
Expert Rev Anticancer Ther; 2006 Jun; 6(6):839-48. PubMed ID: 16761927
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
